Jan 29 (Reuters) - A U.S. trade tribunal sided with Juul Labs on Wednesday and ordered a ban on imports of vaping devices and cartridges made by Altria's (MO.N), opens new tab NJOY - at least some ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with ...

Novo Nordisk (NVO) ended the recent trading session at $84.62, demonstrating a -1.9% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%. At the same ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...

That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale ...

The newly emerged Swiss biotech’s series A financing was led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, with participation from six other industry investors, according to a ...

Minnesota Attorney General Keith Ellison on Monday announced a settlement in a lawsuit against insulin manufacturer Novo Nordisk. Minnesota residents will now be able to get Novo Nordisk insulin ...

Novo Nordisk presents a compelling 'Strong Buy' opportunity with a 51% upside potential. NVO's financial strength is evident through its 74% historical average ROIC, 85% gross margin, and ...

42.3% with de novo acral melanoma (DNAM). Overall 5-year survival was 75.1% vs. 63.2% in the NAAM vs. DNAM groups. Recurrence-free survival and overall survival were more common in patients with ...